Indeed, targeting of MCL-1 has been shown to sensitize cells and effectively inhibit tumor growth in vitro and in vivo when administered in combination with BCL-2/BCL-XL inhibitors [122,127]. The gene discussed is BCL2; the disease is neoplasm.